RBx 7796: A novel inhibitor of 5-lipoxygenase

Inflammation Research

Volumn 55, Issue 12, 2006, Pages 517-527

  Shirumalla, R K ^a   Naruganahalli, K S ^a   Dastidar, S G ^a   Sattigeri, V ^a   Kaur, G ^a   Deb, C ^a   Gupta, J B ^a   Salman, M ^a   Ray, Abhijit ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

5 lipoxygenase; Airway inflammation; Bronchoconstriction; Leukotrienes; RBx 7796

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CALCIMYCIN; LEUKOTRIENE B4; LIPOPOLYSACCHARIDE; LIPOXYGENASE INHIBITOR; OVALBUMIN; RBX 7796; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME INHIBITION; EX VIVO STUDY; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUTROPHILIA; NONHUMAN; RAT; RESPIRATORY TRACT DISEASE; ANIMAL; BRONCHOCONSTRICTION; DRUG EFFECTS; EOSINOPHIL; NEUTROPHIL;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BRONCHOCONSTRICTION; EOSINOPHILS; HUMANS; LIPOXYGENASE INHIBITORS; NEUTROPHILS;

EID: 33846360266     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-6032-z     Document Type: Article

References (49)

1. Barnes PJ. New treatments for chronic obstructive pulmonary disease. Ann Ist Super Sanita 2003; 39: 573-82.
2. Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003; 362: 1053-61.
3. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004; 3: 831-44.
4. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-45.
5. Boushey HA. New and exploratory therapies for asthma. Chest 2003; 123: 439S-45S.
6. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364: 985-96.
7. dE Boer WI. Perspectives for cytokine antagonist therapy in COPD. Drug Discov Today 2005; 10: 93-106.
8. Busse WW. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998; 157: S210-13.
9. Leff AR. Role of leukotrienes in bronchial hyperesponsiveness and cellular responses in airways. Thorax 2000; 55: S32-7.
10. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 2002; 121: 197s-200s.
11. Aharony D. Pharmacology of leukotriene receptor antagonists. Am J Respir Crit Care Med 1998; 157: S214-9.
12. Howarth PH. Methods of assessing LTRA efficacy in humans. Clin Exp Allergy Rev 2001; 1: 220-8.
13. Drazen J. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. Am J Respir Crit Care Med 1998; 157: S233-7.
14. 4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51: 1178-84.
15. Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B4 receptor antagonist. J Pharmacol Exp Ther 2001; 297: 458-66.
16. Werz O. 5-Lipoxygenase: Cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 2002; 1: 23-44.
17. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL et al. 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 1991; 256: 929-37.
18. Bell RL, Bouska JB, Malo PE, Lanni C, Harris RR, Otis ER et al. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. J Pharmacol Exp Ther 1995; 272: 724-31.
19. Bell RL, Harris RR, Malo PE, Bouska JB, Shaughnessy TK, Hulkower KI et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther 1997; 280: 1366-73.
20. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-66.
21. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275: 931-36.
22. Garcia-marcos L, Schuster A, Perez-yarza EG. Benefit risk assessment of antileukotrienes in the management of asthma. Drug Safety 2003; 26: 483-518.
23. Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG et al. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. J Med Chem 1995; 38: 4768-75.
24. Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB et al.. Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. J Med Chem 1997; 40: 1955-68.
25. Kolasa T, Gunn DE, Bhatia P, Woods KW, Gane T, Stewart AO et al. Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors. J Med Chem 2000; 43: 690-705.
26. Brooks CD, Summers JB. Modulators of leukotriene biosynthesis and receptor activation. J Med Chem 1996; 39: 2629-54.
27. Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: Clinical efficacy and safety concerns. Drug Saf 2003; 26: 605-24.
28. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003; 31: 1352-60.
29. Joshi EM, Heasley BH, Chordia MD, Macdonald TL. In vitro metabolism of 2-acetylbenzothiophene: Relevance to zileuton hepatotoxicity. Chem Res Toxicol 2004; 17: 137-43.
30. Turner CR, Smith WB, Andresen CJ, Eggler JF, Watson JW. The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys. Inflamm Res 1996; 45: 42-9.
31. Nasser SM, Bell GS, Hawksworth RJ, Spruce KE, Macmillan R, Williams AJ et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994; 49: 743-8.
32. Keicher U, Koletzko B, Reinhardt D. Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis. Eur J Clin Invest 1995; 25: 915-9.
33. Robinson BS, Rathjen DA, Trout NA, Easton CJ, Ferrante A. Inhibition of neutrophil leukotriene B4 production by a novel synthetic N-3 polyunsaturated fatty acid analogue, beta-oxa 21: 3n-3. J Immunol 2003; 171: 4773-9.
34. Devaraj S, Jialal I. Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic Biol Med 2005; 38: 1212-20.
35. Aharony D, Stein RL. Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J Biol Chem 1986; 261: 11512-9.
36. Hatzelmann A, Ullrich V. Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes. Eur J Biochem 1987; 169: 175-84.
37. 4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297: 267-79.
38. Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 2004; 142: 861-8.
39. Werz O, Szellas D, Henseler M, Steinhilber D. Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 1998; 54: 445-51.
40. Barnes PJ. Small airways in COPD. New Eng J Med 2004; 350: 2635-7.
41. Wheeldon EB, Walker ME, Murphy DJ, Turner CR, Intratracheal aerosolization of endotoxin in the rat: a model of the adult respiratory distress syndrome (ARDS). Lab Anim 1992; 26: 29-37.
42. 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. Pul Pharmacol Ther 2001; 14: 157-64.
43. Fischer L, Szellas D, Radmark O, Steinhilber D, Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J 2003; 17: 949-51.
44. Turner CR, Lackey MN, Quinlan MF, Griswold DE, Schwartz LW, Wheeldon EB. Therapeutic intervention in a rat model of adult respiratory distress syndrome II. Lipoxygenase pathway inhibition. Circ Shock 1991; 34: 263-9.
45. Prieto L, Gutierrez V. The limitations of the functional response model to the bronchial challenge with allergens in asthma. Alergol Immunol Clin 2000; 15: 77-81.
46. Campos MG, Church MK. How useful are guinea pig models of asthma? Clin Exp Allergy 1992; 22: 665-6.
47. Kreutner W, Sherwood J, Rizzo C. The effect of leukotriene antagonists, lipoxygenase inhibitors and selected standards on leukotriene-mediated allergic bronchospasm in guinea pigs. Agents Actions 1989; 28: 173-84.
48. Wegner CD, Gundel, RH, Abraham WM, Schulman ES, Kontny MJ, Lazer ES et al. The role of 5-lipoxygenase products in preclinical models of asthma. J Aller Clin Immunol, 1993; 91: 917-29.
49. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol, 1995; 73: 191-201.